164 related articles for article (PubMed ID: 37493526)
1. Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
Corlett A; Pinson JA; Rahimi MN; Zuylekom JV; Cullinane C; Blyth B; Thompson PE; Hutton CA; Roselt PD; Haskali MB
J Med Chem; 2023 Aug; 66(15):10289-10303. PubMed ID: 37493526
[TBL] [Abstract][Full Text] [Related]
2. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
3. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
5. [
Lezaic L; Erba PA; Decristoforo C; Zaletel K; Mikolajczak R; Maecke H; Maina T; Konijnenberg M; Kolenc P; Trofimiuk-Müldner M; Przybylik-Mazurek E; Virgolini I; de Jong M; Fröberg AC; Rangger C; Di Santo G; Skorkiewicz K; Garnuszek P; Solnica B; Nock BA; Fedak D; Gaweda P; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):892-907. PubMed ID: 36334104
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
7. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.
Aloj L; Aurilio M; Rinaldi V; D'ambrosio L; Tesauro D; Peitl PK; Maina T; Mansi R; von Guggenberg E; Joosten L; Sosabowski JK; Breeman WA; De Blois E; Koelewijn S; Melis M; Waser B; Beetschen K; Reubi JC; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1417-25. PubMed ID: 21523391
[TBL] [Abstract][Full Text] [Related]
9. Precision peptide theranostics: developing
Rahimi MN; Corlett A; Van Zuylekom J; Sani MA; Blyth B; Thompson P; Roselt PD; Haskali MB
Theranostics; 2024; 14(5):1815-1828. PubMed ID: 38505611
[TBL] [Abstract][Full Text] [Related]
10. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
11.
Rangger C; Klingler M; Balogh L; Pöstényi Z; Polyak A; Pawlak D; Mikołajczak R; von Guggenberg E
Mol Pharm; 2017 Sep; 14(9):3045-3058. PubMed ID: 28728415
[TBL] [Abstract][Full Text] [Related]
12. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
13. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
[TBL] [Abstract][Full Text] [Related]
14. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
15. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
Wayua C; Low PS
J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
[TBL] [Abstract][Full Text] [Related]
17. Automated Synthesis of
Hörmann AA; Plhak E; Klingler M; Rangger C; Pfister J; Schwach G; Kvaternik H; von Guggenberg E
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335396
[TBL] [Abstract][Full Text] [Related]
18. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.
Kaloudi A; Nock BA; Lymperis E; Sallegger W; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2015 Nov; 42(11):824-32. PubMed ID: 26300210
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]